A Phase 1/2 interventional study of Cabazitaxel (XRP6258) in Malignant Solid Tumor - Malignant Nervous System Neoplasm, sponsored by Sanofi. Completed at 13 sites in 2 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2016-08-12.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Nervous System Neoplasms with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Nervous System Neoplasms · United States.
Among the 14 studies in Nervous System Neoplasms with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 1/2, and was the 9th registered.
19 studies on the registry are indexed under Nervous System Neoplasms; 8 are open to participants now.
Browse Nervous System Neoplasms studies →6 of the 14 studies in Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of California, Irvine · Sites in United States
Ages 18+
Cerenome · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 4–21
M.D. Anderson Cancer Center · Sites in United States
Ages 36 mo–22 yrs
University of Florida · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Nervous System Neoplasms studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6
First in 2006; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is above the median of 32 across 14 interventional studies indexed under Nervous System Neoplasms.
Median enrollment 32 across the 12 interventional studies, 2,006 across the 2 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 14 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Nervous System Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Nervous System Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05762419Columbia UniversityFUS Etoposide for DMG | 2026-12 |
| NCT05746104Abramson Cancer Center at Penn MedicineSecond Window Indocyanine Green for All Nervous System Tumors | 2027-02-15 |
| NCT07098806CerenomeMultiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Nervous System Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Phase 1 Part:
To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cabazitaxel as a single agent in pediatric participants with recurrent or refractory solid tumors including tumors of the central nervous system.
Phase 2 Part:
To determine the objective response rate (complete and partial response) and the duration of response to cabazitaxel as a single agent in participants with recurrent or refractory high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG).
Secondary Objectives:
Phase 1 Part:
To characterize the safety and tolerability of cabazitaxel in participants with recurrent or refractory solid tumors including tumors of the central nervous system.
To characterize the pharmacokinetic (PK) profile of cabazitaxel in participants with recurrent or refractory solid tumors including tumors of the central nervous system.
To evaluate preliminary anti-tumor activity that may be associated with cabazitaxel in participants with recurrent or refractory solid tumors including tumors of the central nervous system.
Phase 2 Part:
To characterize the safety and tolerability of cabazitaxel in participants with recurrent or refractory HGG or DIPG.
To estimate progression free survival in participants with recurrent or refractory HGG or DIPG.
To estimate overall survival in participants with recurrent or refractory HGG or DIPG.
To characterize the plasma PK profile of cabazitaxel in participants with recurrent or refractory HGG or DIPG.
The study duration will include a period for inclusion of up to 3 weeks and a 3-week treatment cycle(s). The participants may continue treatment until disease progression, unacceptable toxicity or willingness to stop followed by a minimum of 30-day follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1 Part (dose escalation): Participants with a confirmed solid tumor including tumors of the central nervous system that was recurrent or and for which no further effective standard treatment was available. All participants must had . Participants with diffuse pontine glioma were eligible without a after evidence of progressive disease post radiation therapy.
Phase 2 Part (safety and activity): Participants with recurrent or refractory high grade glioma or diffuse intrinsic pontine glioma for whom no further effective therapy was available. All participants must had measurable disease. Participants with diffuse pontine glioma were eligible without a biopsy after evidence of progressive disease post radiation therapy. Participants with a grade III or grade IV glioma must had pathologic confirmation either at the time of initial diagnosis or at the time of recurrence.
Participants aged ≥2 years and ≤18 years
Participants met the body surface area (BSA) requirements to be eligible:
Performance status by:
Participants must had adequate liver, renal and marrow function as defined below:
Female participants of must had a negative pregnancy test ≤7 days before starting cabazitaxel treatment.
Male and female participants of must agreed to use adequate prior to study entry, for the duration of study participation and for 6 months following the last dose of cabazitaxel.
Written /assent prior to any study-specific procedures. Consent must be obtained from the participant and/or parent(s) or legal guardian(s) and the signature of at least one parent or guardian was required. Investigators also obtained assent of participants according to local, regional or national guidelines.
Participants must have recovered from the acute toxic effects of all prior therapy to ≤ grade 1 before entering the study.
Exclusion criteria:
Prior treatment within the following timeframes:
Prior systemic radioisotope therapy (this did not include diagnostic imaging or radioimmunoconjugates lacking myelosuppressive properties) or total body irradiation.
Prior bone marrow or stem cell transplant
Participants with any illness that, in the investigator's opinion, could not be adequately controlled with appropriate therapy, would compromise a participant's ability to tolerate cabazitaxel or result in inability to assess toxicity. This included, but was not limited to uncontrolled intercurrent illness including ongoing or active infection, cardiac disease, renal impairment, planned surgery or psychiatric illness/social situations that would limit compliance with study requirements.
Known (HIV) infection or acquired immunodeficiency-syndrome (AIDS)-related disease Known history of or known active infection. Pregnant or breast feeding women Treatment with strong inhibitors or strong inducers of or enzyme inducing anti-epileptic drugs (EIAED) within 14 days prior to first dose of cabazitaxel and for the duration of study. Non-EIAEDs were permitted.
Known history of to taxanes or polysorbate 80 or G-CSF. Participation in another interventional clinical trial and/or concurrent treatment with any investigational drug.
Participants not able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).
Drug: Cabazitaxel (XRP6258)
Cabazitaxel 25 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
Drug: Cabazitaxel (XRP6258)
Cabazitaxel 30 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
Drug: Cabazitaxel (XRP6258)
Cabazitaxel 35 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
Drug: Cabazitaxel (XRP6258)
Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m\^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
Drug: Cabazitaxel (XRP6258)
Pharmaceutical form: Injection Route of administration: Intravenous
Also known as: Jevtana
Phase 1: Maximum Tolerated Dose of Cabazitaxel
MTD was highest dose level of cabazitaxel at which no more than 1 of 6 evaluable participants experienced dose limiting toxicities (DLT). DLT defined as an AE or abnormal laboratory values related to study treatment: hematologic DLTs: any Grade(G)4 hematologic toxicity except neutropenia G4 lasting≤7 days,G3 or 4 febrile neutropenia except G3 or 4 febrile neutropenia in absence of granulocyte-colony stimulating factor prophylaxis, G4 thrombocytopenia; non-hematologic DLTs:any G≥3 non-hematologic toxicity except G3 nausea or G3 or4 vomiting, G3 or4 diarrhea,G3 or4 dehydration,G3 fatigue lasting≤7 days, inadequately treated hypersensitivity reactions, elevated transaminases\<10\* upper limit of normal of ≤7 days, re-treatment delay of\>2 weeks due to delayed recovery from toxicity related to study treatment to baseline G or≤ G1(except for alopecia) and platelet transfusion during Cycle1. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Time frame: Cycle 1 (21 days)
Phase 2: Percentage of Participants With Objective Response (OR)
OR in participants was defined as the participants with a Complete Response (CR) or Partial Response (PR) after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks. CR and PR were based on modified response assessment in neuro-oncology (RANO) criteria for participants with CNS tumors. CR was defined as disappearance of all target lesions. PR was defined as ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to the baseline measurement.
Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)
Phase 2: Duration of Response (DOR)
DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. If progression or death was not observed, participant was censored at the date of participant's last progression-free tumor assessment prior to study cut-off date. PD as per RANO criteria was defined as ≥ 25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc.) plus any increase in tumor cross-sectional area (or tumor volume).
Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)
Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. Treatment emergent adverse events (TEAEs) were defined as AEs that developed or worsened in grade or became serious during the on-treatment period which was defined as the period from the time of first dose of cabazitaxel until 30 days following the last administration of cabazitaxel.
Time frame: Baseline up to DP or death due to any cause (maximum duration: 112.1 weeks for Phase 1 and 12.1 weeks for Phase 2)
Phase 1: Number of Participants With Objective Response
OR in participants was defined as the participants with a CR or PR after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1 and RANO criteria for CNS tumors. For solid tumors, as per RECIST 1.1, CR defined as disappearance of all target and non-target lesions (any pathological lymph nodes, must had reduction in short axis to \<10 mm); PR defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. For CNS tumors, as per RANO criteria, CR defined as disappearance of all target and non-target lesions; PR defined as a ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to baseline measurement.
Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 112.1 weeks)
Phase 1 and 2: Pharmacokinetics (PK) Parameter of Cabazitaxel: Area Under the Plasma Concentration (AUC) Versus Time Curve
Blood samples for PK parameters were collected at 5 minutes before end of infusion (EOI), 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Phase 1 and 2: PK Parameter of Cabazitaxel: Total Plasma Clearance (CL)
Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Phase 1 and 2: PK Parameter of Cabazitaxel: Volume of Distribution at Steady State (Vss)
Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Phase 1 and 2: PK Parameter of Cabazitaxel: Maximum Plasma Concentration Observed (Cmax)
Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
Time frame: Day 1 of Cycle 1: 5 minutes before EOI up to 71 hours after the EOI
Phase 2: Progression Free Survival (PFS)
The PFS was defined as the time (in months) from the date of first dose administration until the date of first documented PD or death (from any cause), whichever came first. If progression or death was not observed, the participant was censored at the date of the participant's last progression-free tumor assessment prior to the study cut-off date. PD as per RANO criteria was defined as ≥25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc) plus any increase in tumor cross-sectional area (or tumor volume). The analysis was performed by Kaplan-Meier method.
Time frame: Baseline, every 9 weeks until DP or death due to any cause (maximum duration: 12.1 weeks)
Phase 2: Overall Survival (OS)
OS was defined as the time (in months) from the date of first dose administration until the date of death (from any cause). If death was not observed, the participant was censored at the earliest of the last date the participant was known to be alive and the study cut-off date. The analysis was performed by Kaplan-Meier method.
Time frame: Baseline up to death or study cut-off (maximum duration: 12.1 weeks)
Participants were enrolled at 12 centers between February 2013 and March 2015.
| Milestone | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|---|---|---|---|
| Started | 6 | 3 | 7 | 7 | 0 |
| Completed | 6 | 3 | 7 | 7 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 16 |
| Completed | 0 | 0 | 0 | 0 | 16 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
MTD was highest dose level of cabazitaxel at which no more than 1 of 6 evaluable participants experienced dose limiting toxicities (DLT). DLT defined as an AE or abnormal laboratory values related to study treatment: hematologic DLTs: any Grade(G)4 hematologic toxicity except neutropenia G4 lasting≤7 days,G3 or 4 febrile neutropenia except G3 or 4 febrile neutropenia in absence of granulocyte-colony stimulating factor prophylaxis, G4 thrombocytopenia; non-hematologic DLTs:any G≥3 non-hematologic toxicity except G3 nausea or G3 or4 vomiting, G3 or4 diarrhea,G3 or4 dehydration,G3 fatigue lasting≤7 days, inadequately treated hypersensitivity reactions, elevated transaminases\<10\* upper limit of normal of ≤7 days, re-treatment delay of\>2 weeks due to delayed recovery from toxicity related to study treatment to baseline G or≤ G1(except for alopecia) and platelet transfusion during Cycle1. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
| mg/m^2 | Phase 1: Overall Population |
|---|---|
| Phase 1: Maximum Tolerated Dose of Cabazitaxel | 30 |
OR in participants was defined as the participants with a Complete Response (CR) or Partial Response (PR) after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks. CR and PR were based on modified response assessment in neuro-oncology (RANO) criteria for participants with CNS tumors. CR was defined as disappearance of all target lesions. PR was defined as ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to the baseline measurement.
| percentage of participants | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|
| CR | 0 |
| PR | 0 |
DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. If progression or death was not observed, participant was censored at the date of participant's last progression-free tumor assessment prior to study cut-off date. PD as per RANO criteria was defined as ≥ 25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc.) plus any increase in tumor cross-sectional area (or tumor volume).
No measurements were reported for this outcome.
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. Treatment emergent adverse events (TEAEs) were defined as AEs that developed or worsened in grade or became serious during the on-treatment period which was defined as the period from the time of first dose of cabazitaxel until 30 days following the last administration of cabazitaxel.
| participants | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|---|---|---|---|
| Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 6 | 3 | 7 | 7 | 16 |
OR in participants was defined as the participants with a CR or PR after 3 cycles of cabazitaxel treatment and maintained for at least 4 weeks as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1 and RANO criteria for CNS tumors. For solid tumors, as per RECIST 1.1, CR defined as disappearance of all target and non-target lesions (any pathological lymph nodes, must had reduction in short axis to \<10 mm); PR defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. For CNS tumors, as per RANO criteria, CR defined as disappearance of all target and non-target lesions; PR defined as a ≥50% decrease in the sum of the products of the two perpendicular diameters of target lesions, compared to baseline measurement.
| participants | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 |
|---|---|---|---|---|
| Phase 1: Number of Participants With Objective Response | 1 | 0 | 0 | 0 |
Blood samples for PK parameters were collected at 5 minutes before end of infusion (EOI), 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
| ng.h/mL | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1 and 2: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 |
|---|---|---|---|---|
| Phase 1 and 2: Pharmacokinetics (PK) Parameter of Cabazitaxel: Area Under the Plasma Concentration (AUC) Versus Time Curve | 669.5 ± 430.6 | 879.0 ± 414.7 | 876.7 ± 359.9 | 1002.5 ± 277.9 |
Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
| L/h/m^2 | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1 and 2: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 |
|---|---|---|---|---|
| Phase 1 and 2: PK Parameter of Cabazitaxel: Total Plasma Clearance (CL) | 36.05 ± 12.91 | 32.76 ± 12.72 | 38.70 ± 12.98 | 36.61 ± 9.98 |
Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
| L/m^2 | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1 and 2: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 |
|---|---|---|---|---|
| Phase 1 and 2: PK Parameter of Cabazitaxel: Volume of Distribution at Steady State (Vss) | 3391.72 ± 686.79 | 3301.96 ± 351.55 | 3371.30 ± 975.98 | 1488.75 ± 1179.11 |
Blood samples for PK parameters were collected at 5 minutes before EOI, 10 minutes, 30 minutes, 3 hours, 7 hours and 71 hours after the EOI on Day 1 of Cycle 1.
| ng/mL | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1 and 2: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 |
|---|---|---|---|---|
| Phase 1 and 2: PK Parameter of Cabazitaxel: Maximum Plasma Concentration Observed (Cmax) | 204.864 ± 189.864 | 283.657 ± 242.970 | 256.734 ± 127.931 | 233.290 ± 0.127 |
The PFS was defined as the time (in months) from the date of first dose administration until the date of first documented PD or death (from any cause), whichever came first. If progression or death was not observed, the participant was censored at the date of the participant's last progression-free tumor assessment prior to the study cut-off date. PD as per RANO criteria was defined as ≥25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product observed since the start of treatment or the appearance of one or more new lesions, or worsening neurologic status not explained by causes unrelated to tumor progression (example, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc) plus any increase in tumor cross-sectional area (or tumor volume). The analysis was performed by Kaplan-Meier method.
| months | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|
| Phase 2: Progression Free Survival (PFS) | 1.3 (0.6 to 2.1) |
OS was defined as the time (in months) from the date of first dose administration until the date of death (from any cause). If death was not observed, the participant was censored at the earliest of the last date the participant was known to be alive and the study cut-off date. The analysis was performed by Kaplan-Meier method.
| months | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|
| Phase 2: Overall Survival (OS) | 2.7 (1.7 to 4.5) |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (112.1 weeks for Phase 1 and 12.1 weeks for Phase 2) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Cabazitaxel 20 mg/m^2 | — | 4/6 (66.7%) | 6/6 (100%) |
| Phase 1: Cabazitaxel 25 mg/m^2 | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1: Cabazitaxel 30 mg/m^2 | — | 5/7 (71.4%) | 7/7 (100%) |
| Phase 1: Cabazitaxel 35 mg/m^2 | — | 3/7 (42.9%) | 7/7 (100%) |
| Phase 2: Cabazitaxel 30 mg/m^2 | — | 12/16 (75%) | 15/16 (93.8%) |
| Event | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 1/3 | 1/7 | 2/7 | 3/16 |
| Varicella zoster virus infectionInfections and infestations | 0/6 | 1/3 | 0/7 | 0/7 | 0/16 |
| Platelet count decreasedInvestigations | 0/6 | 1/3 | 0/7 | 0/7 | 0/16 |
| Disease progressionGeneral disorders | 1/6 | 0/3 | 0/7 | 0/7 | 3/16 |
| Anaphylactic reactionImmune system disorders | 0/6 | 0/3 | 0/7 | 0/7 | 3/16 |
| GastroenteritisInfections and infestations | 1/6 | 0/3 | 0/7 | 0/7 | 0/16 |
| Intracranial tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/3 | 1/7 | 0/7 | 1/16 |
| Cystitis noninfectiveRenal and urinary disorders | 1/6 | 0/3 | 0/7 | 0/7 | 0/16 |
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 0/3 | 1/7 | 0/7 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/3 | 0/7 | 1/7 | 2/16 |
| Event | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 | Phase 2: Cabazitaxel 30 mg/m^2 |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/6 | 2/3 | 3/7 | 2/7 | 4/16 |
| HeadacheNervous system disorders | 4/6 | 1/3 | 1/7 | 2/7 | 4/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 2/3 | 3/7 | 1/7 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 1/3 | 4/7 | 1/7 | 5/16 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/3 | 1/7 | 3/7 | 2/16 |
| NauseaGastrointestinal disorders | 2/6 | 1/3 | 3/7 | 2/7 | 5/16 |
| FatigueGeneral disorders | 2/6 | 1/3 | 2/7 | 3/7 | 3/16 |
| DysphagiaGastrointestinal disorders | 0/6 | 0/3 | 0/7 | 0/7 | 6/16 |
| AnaemiaBlood and lymphatic system disorders | 1/6 | 1/3 | 2/7 | 1/7 | 1/16 |
| Sinus tachycardiaCardiac disorders | 1/6 | 1/3 | 1/7 | 1/7 | 0/16 |
All treated (AT)/safety population was defined as all registered participants who actually received at least 1 dose or part of a dose of the investigational medicinal product (IMP).
| Age, Customized(participants) | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 | Phase 2: Cabazitaxel 30 mg/m^2 | Total |
|---|---|---|---|---|---|---|
| 2-4 years | 0 | 0 | 2 | 0 | 2 | 4 |
| 5-6 years | 2 | 1 | 0 | 1 | 4 | 8 |
| 7-11 years | 1 | 1 | 3 | 5 | 4 | 14 |
| 12-18 years | 3 | 1 | 2 | 1 | 6 | 13 |
| Sex: Female, Male(Participants) | Phase 1: Cabazitaxel 20 mg/m^2 | Phase 1: Cabazitaxel 25 mg/m^2 | Phase 1: Cabazitaxel 30 mg/m^2 | Phase 1: Cabazitaxel 35 mg/m^2 | Phase 2: Cabazitaxel 30 mg/m^2 | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 0 | 1 | 2 | 8 | 16 |
| Male | 1 | 3 | 6 | 5 | 8 | 23 |
The record gives a start of Feb 2013, a primary completion of Jul 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabazitaxel